--- title: "ALS SPG302 Expanded Access Protocol | Sutter Health" description: "Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)" url: "https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. ALS SPG302 Expanded Access Protocol # ALS SPG302 Expanded Access Protocol **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/study/NCT07088159). #### Locations - San Francisco #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) ![Liberty Jenkins, M.D., MRCP, MA](https://dyn.mktgcdn.com/p/hIKxbkNyvPTZvlOmGO-wJv3aYSMD_I0MA4-etx40fnU/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Liberty Jenkins, M.D., MRCP, MA Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/liberty-jenkins-md-mrcp-ma-1049681060) ## Email us to enroll - [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20ALS%20SPG302%20Expanded%20Access%20Protocol%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [ALS Healey Platform Trial Master Protocol](https://www.sutterhealth.org/research/clinical-trials/als-healey-platform-trial-master-protocol-2057369170) HEALEY ALS Platform Trial **Status:** Closed to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) C302-CLN-2301](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-c302-cln-2301-2044044761) Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) **Status:** Open to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) PL101-ALS301 PREVAILS](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-pl101-als301-prevails-2064309735) A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis **Status:** Open to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) UNITE-ALS USNO.24.002](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-unite-als-usno24002-2064309948) A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS UNITE-ALS USNO.24.002 **Status:** Open to Enrollment - Clinical trial ### [Acute Ischemic Stroke PICASSO](https://www.sutterhealth.org/research/clinical-trials/acute-ischemic-stroke-picasso-1094825919) Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"ALS SPG302 Expanded Access Protocol"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358#medicalwebpage","name":"ALS SPG302 Expanded Access Protocol","description":"Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)","url":"https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358","inLanguage":"en-US","dateModified":"2026-05-19","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358#breadcrumblist"},"mentions":[{"@type":"Person","name":"Liberty Jenkins, M.D., MRCP, MA","url":"https://www.sutterhealth.org/research/investigators/liberty-jenkins-md-mrcp-ma-1049681060","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358#medicaltrial","name":"ALS SPG302 Expanded Access Protocol","alternateName":"Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)","url":"https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358","description":"Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)","identifier":"NCT07088159","code":{"@type":"MedicalCode","codeValue":"NCT07088159","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/study/NCT07088159","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Amyotrophic Lateral Sclerosis (ALS)"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"}]} ```